Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 7/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20351058 | 0.89 | ALDH1A1 (0.48) | ALDH1A1TSHRHPGDTDP1KDM4E | |
| SCHEMBL20339853 | 0.83 | KDM4E (0.60) | ALDH1A1TSHRHPGDTDP1KDM4E | |
| SCHEMBL14110743 | 0.82 | TSHR (0.70) | ALDH1A1TSHRHPGDTDP1KDM4E | |
| SCHEMBL12818167 | 0.80 | ALDH1A1 (0.78) | ALDH1A1TSHRHPGDTDP1KDM4E | |
| SCHEMBL20350859 | 0.78 | ALDH1A1 (0.51) | ALDH1A1TSHRHPGDTDP1KDM4E | |
| SCHEMBL4905153 | 0.75 | KDM4E (0.58) | ALDH1A1TSHRHPGDTDP1KDM4E | |
| SCHEMBL20339496 | 0.73 | KDM4E (0.70) | ALDH1A1TSHRHPGDTDP1KDM4E | |
| SCHEMBL20340043 | 0.72 | KDM4E (0.64) | ALDH1A1TSHRHPGDTDP1KDM4E | |
| SCHEMBL2586136 | 0.67 | KDM4E (0.66) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL8884786 | 0.67 | ALDH1A1 (0.76) | ALDH1A1TSHRHPGDKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1673374-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005035537-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | LTC4S, NQO1, CBR3 | ALDH1A1 270/4885TSHR 2558/4885HPGD 53/4885 |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | LTC4S, NQO1, CBR3 | ALDH1A1 270/4885TSHR 2558/4885HPGD 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.